Published in final edited form as:

Bioorg Med Chem. 2008 January 15; 16(2): 692–698.

Inactivation of Human Neutrophil Elastase by 1, 2, 5 – Thiadiazolidin-3-one 1, 1 Dioxide-based Sulfonamides

Yi Li, Qingliang Yang, Dengfeng Dou, Kevin R. Alliston, and William C. Groutas*

Department of Chemistry, Wichita State University, Wichita, Kansas 67260

Abstract

The interaction of a series of 1, 2, 5 –thiadiazolidin-3-one 1, 1 dioxide-based sulfonamides with neutrophil-derived serine proteases was investigated. The nature of the amino acid component, believed to be oriented toward the S' subsites, had a profound effect on enzyme selectivity. This series of compounds were found to be potent, time-dependent inhibitors of human neutrophil elastase (HNE) and was devoid of any inhibitory activity toward neutrophil proteinase 3 (PR 3) and cathepsin G (Cat G). The results of these studies demonstrate that exploitation of differences in the S' subsites of HNE and PR 3 can lead to highly selective inhibitors of HNE.

Introduction

The neutrophil-derived serine endopeptidases human neutrophil elastase (HNE), proteinase 3 (PR 3) and cathepsin G (Cat G) have been implicated in a range of inflammatory diseases, including chronic obstructive pulmonary disease (COPD).¹ Although the pathogenesis of COPD is poorly understood, current studies indicate that this multifactorial disorder is characterized by a cigarette smoke-induced cycle of oxidative stress,² alveolar septal cell apoptosis,³ a protease/antiprotease imbalance,⁴ and chronic inflammation.⁵ An array of serine (HNE, PR 3, Cat G), cysteine (cathepsin S) and metallo- (MMP-9, MMP-12) proteases released by neutrophils, macrophages and T lymphocytes contribute to the degradation of lung connective tissue and mediate a multitude of signaling pathways associated with the pathophysiology of the disorder.⁶ Consequently, pharmacological agents capable of abrogating or modulating the aberrant proteolytic activity of the aforementioned enzymes are of potential therapeutic value.⁷

We have recently described the design and *in vitro* biochemical evaluation of a novel class of mechanism-based inhibitors (I) that inactivate target serine proteases via an unprecedented enzyme-induced sulfonamide fragmentation process (Figure 1).⁸ Sulfonamide inhibitor (I) embodies in its structure a functionalized heterocyclic scaffold with appended recognition elements for optimal exploitation of binding interactions with the S_n and S_n' subsites⁹ of the target enzyme. Derivatives of inhibitor (I) (R₁ = isobutyl, R₂ = methyl) were previously found to inactivate HNE efficiently, however they also showed significant inhibitory activity toward trypsin despite the lack of a basic P₁ residue. In an effort to optimize the inhibitory potency and selectivity of (I) toward HNE and PR 3, recognition element R₃ was varied using a series of amino acid esters and the inhibitory activity of the resulting compounds toward HNE, PR

*author to whom correspondence should be addressed: Department of Chemistry, Wichita State University, Wichita, Kansas 67260, Tel.: (316) 978 7374, Fax: (316) 978 3431, e-mail: bill.groutas@wichita.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

3, Cat G and bovine trypsin was then evaluated. The results of these studies are described herein.

Results

Chemistry

Compounds **4-11** were synthesized starting with (L) norvaline using the sequence of steps shown in Scheme 1. Key intermediate **1** was synthesized using similar procedures as those described previously.^{8b} The synthetic methodology was straightforward, however the reaction sequence involving the conversion of the thioesters to the corresponding sulfinyl chlorides which, without isolation, were reacted with the amino acid esters, was found to be capricious and gave low yields (10-20%) of the sulfinamide products. Optimization of the reaction conditions and monitoring product formation using ¹H NMR, improved yields somewhat (30%).

Biochemical Studies

Progress curve method—The inhibitory activity of compounds **4-11** toward HNE was determined by the progress curve method.^{10, 8b} The apparent second-order rate constants ($k_{\text{inact}}/K_I \text{ M}^{-1} \text{ s}^{-1}$) were determined in duplicate and are listed in Table 1. Typical progress curves for the hydrolysis of MeOSuc-AAPV-pNA by HNE in the presence of inhibitor **4** are shown in Figure 2. The release of p-nitroaniline was continuously monitored at 410 nm. The pseudo first-order rate constants (k_{obs}) for the inhibition of HNE by derivatives of (**1**) as a function of time were determined according to eq 1 below, where A is the absorbance at 410 nm, v_0 is the reaction velocity at $t = 0$, v_s is the final steady-state velocity, k_{obs} is the observed first-order rate constant, and A_0 is the absorbance at $t = 0$. The k_{obs} values were obtained by fitting the $A \sim t$ data into eq 1 using nonlinear regression analysis (SigmaPlot, Jandel Scientific). The second order rate constants ($k_{\text{inact}}/K_I \text{ M}^{-1} \text{ s}^{-1}$) were then determined by calculating $k_{\text{obs}}/[I]$ and then correcting for the substrate concentration using eq 2. Control curves in the absence of inhibitor were linear.

$$A = v_s t + \{(v_0 - v_s) (1 - e^{-k_{\text{obs}} t})/k_{\text{obs}}\} + A_0 \quad \text{eq 1}$$

$$k_{\text{obs}}/[I] = (k_{\text{inact}}/K_I) [1 + [S]/K_m] \quad \text{eq 2}$$

Incubation Method—The inhibitory activity of compounds **4-11** toward trypsin was determined using the incubation method^{8b} and is expressed in terms of the bimolecular rate constant $k_{\text{obs}}/[I] \text{ M}^{-1} \text{ s}^{-1}$, where k_{obs} is the pseudo-first order rate constant of enzyme inactivation and $[I]$ is the concentration of the inhibitor in the incubation mixture. Briefly, in this method the enzyme is incubated with excess inhibitor and the loss of enzymatic activity is followed by withdrawing aliquots at different time intervals and assaying for enzymatic activity. The observed rate constants (k_{obs}) are then determined by plotting $\ln([E_t]/[E_0])$ versus t according to equation 3 below, where $[E_t]/[E_0]$ is the amount of active enzyme remaining at time t . These are the average of two or three determinations.

$$\ln([E_t]/[E_0]) = -k_{\text{obs}} t \quad \text{eq 3}$$

Discussion

Inhibitor Design

The design of inhibitor (**1**) is briefly summarized below: (a) in contrast to ordinary peptides, α -sulfonylpeptides (α -amido sulfonylamides) undergo a spontaneous fragmentation reaction to yield a Michael acceptor (Figure 1); (b) inhibitor (**1**) is a stable molecule which also embodies

in its structure an α -sulfonopeptide motif (Figure 1(b)). Based on the mechanism of action of serine proteases, it was envisaged that embellishment of (I) with appropriate recognition elements would allow (I) to bind to the active site of a target serine protease, leading to the formation of a tetrahedral intermediate that would subsequently collapse via a sulfonamide fragmentation-driven process to generate a Michael acceptor. Formation of a stable enzyme-inhibitor adduct was anticipated to lead to inactivation of the enzyme; (c) HNE and PR 3 play an important role in inflammatory diseases such as COPD^{1,11} and cystic fibrosis.¹² Furthermore, both enzymes hydrolyze lung elastin, the hydrophobic component of lung connective tissue, with high efficiency and also induce emphysema in hamsters when administered intratracheally.¹³ Consequently, in order for (I) to inhibit *both* enzymes, an *n*-propyl group was chosen as the P₁ residue (*vide infra*); (d) an R₂ = methyl group was chosen at S₂ based on earlier studies which demonstrated that the presence of a methyl group at R₂ leads to the formation of highly stable acyl enzymes;¹⁴ and (e) there are significant structural differences in the make up of the S_n' subsites of serine proteases, consequently it was anticipated that varying R₃ may enhance the selectivity of (I). Literature precedent regarding the successful exploitation of S'-P' interactions in the design of potent and selective inhibitors of serine¹⁵ and cysteine¹⁶ proteases provided a strong measure of assurance about the soundness of the approach. As stated earlier, our primary objective was to obtain a derivative of (I) that would display high potency and selectivity toward HNE and PR 3 over other serine proteases.

Recent studies in our laboratory have demonstrated that inhibitor (I) is a highly efficient inhibitor of HNE that inactivates the enzyme via an enzyme-induced sulfonamide fragmentation process.^{8b} However, derivatives of (I) were also found to inhibit trypsin, consequently this report details our studies aimed at gaining further insight into the interaction of (I) with (chymo)trypsin-like serine proteases and optimizing inhibitory activity and enzyme selectivity by varying R₃, the recognition element believed to interact with the S_n' subsites. While all three neutrophil-derived serine proteases (HNE, PR 3, and Cat G) were studied with the synthesized inhibitors, our main efforts were focused on the identification of a dual HNE and PR 3 inhibitor suitable for further development.

Inhibitors **4-11** were all found to be efficient inhibitors of HNE (Table 1). For instance, incubation of compound **4** with HNE lead to rapid, time-dependent, irreversible loss of enzymatic activity (Figure 3). The enzyme did not regain any activity after 24 h, suggesting the formation of a fairly stable enzyme-inhibitor adduct. With the exception of compound **10**, compounds bearing hydrophobic R₃ groups exhibited higher inhibitory activity toward HNE. While this is likely a reflection of the strong preference of HNE for hydrophobic inhibitors (and substrates), rather than the effect of any specific hydrophobic interactions, the high potency of compound **4** may arise from a π - π stacking interaction between Phe 41 in HNE and the phenyl group of the inhibitor.

Quite surprisingly, compounds **4-11** were all devoid of any inhibitory activity toward PR 3 (following incubation at an [I]/[E] ratio of 250), exhibiting absolute selectivity between HNE and PR 3. This remarkable observation is in sharp contrast to previously reported studies that showed that 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide-based derivatives are highly effective inhibitors of both HNE and PR 3.¹⁷ The fact that compounds **4-11** show no inhibitory activity toward PR 3 is probably a reflection of the significant structural differences in the make up of the S_n' subsites of the two enzymes.¹⁸⁻¹⁹ While HNE and PR 3 are highly homologous (57%) and their active sites have some general features in common, namely, they both have extended binding sites and prefer hydrophobic substrates and inhibitors, nevertheless there are also significant differences between the two enzymes. Specifically, interactions beyond the S₁' subsite have a profound effect on catalysis in the case of PR 3 but not HNE.^{19a} Furthermore, the S_n' subsites of PR 3 are decidedly more polar than those of HNE due to the presence of

Asp 61 and Arg 143, which may partly account for the ability of these compounds to discriminate between the two enzymes.¹⁸ These observations are of particular relevance to the design of HNE and PR 3 inhibitors since their primary substrate specificities are very similar (HNE and PR 3 show a preference for (Val, Leu) and (Abu, Norval) respectively, at P₁), consequently varying the nature of the primary specificity residue P₁ may not be sufficient to attain high selectivity. Recently the differences in the S₂ and S₁'-S₃' subsites of PR 3 and HNE have been successfully exploited in the design of highly specific substrates of HNE and PR 3.¹⁹ Furthermore, recent kinetic and molecular modeling analysis studies have reinforced the importance of the charge distribution differences at the active sites of the two enzymes.²⁰ Although the reasons for the noteworthy selectivity exhibited by the compounds used in these studies are not intuitively obvious, their potential utility as pharmacological probes is clearly evident.

As expected, compounds **4-11** showed no activity toward neutrophil cathepsin G (following incubation at an [I]/[E] ratio of 250 for 30 minutes). This is no doubt due to the strong preference of Cat G for a Phe residue at P₁.²¹

Compounds **4-11** were also found to inhibit bovine trypsin in a time-dependent fashion, albeit much less efficiently (Table 1). For instance, incubation of compound **4** with bovine trypsin led to time-dependent inactivation of the enzyme with partial recovery of enzymatic activity after 24 h (Figure 4). The observed inhibitory activity toward trypsin may be due to partial occupation of the S₁ pocket by the n-propyl group in a way that is conducive to binding, namely, by not clashing with the Asp residue at the bottom of the trypsin S₁ pocket.

In conclusion, a series of compounds that shows high potency and selectivity toward HNE but no activity toward PR 3 and Cat G is reported. Further studies aimed at enhancing the HNE/trypsin selectivity ratio and illuminating the structural basis for the selectivity observed with this class of compounds are currently in progress.

Experimental

General

Melting points were recorded on a Mel-Temp apparatus and are uncorrected. The ¹H and ¹³C NMR spectra of the synthesized compounds were recorded on a Varian XL-300 or XL-400 spectrometers. Human neutrophil elastase, proteinase 3 and Boc-Ala-Ala-Nva thiobenzyl ester were purchased from Elastin Products Co., Owensville, MO. Bovine trypsin, methoxysuccinyl Ala-Ala-Pro-Val *p*-nitroanilide, succinyl Ala-Ala-Pro-Phe *p*-nitroanilide, N-(*p*-Tosyl)-Gly-Pro-Lys 4-nitroanilide and 5, 5' -dithio-bis(2-nitrobenzoic acid) were purchased from Sigma Chemicals Co., St Louis, MO. Human neutrophil cathepsin G was purchased from Athens Research and Technology Co., Athens, GA. Silica gel (230-450 mesh) used for flash chromatography was purchased from Sorbent Technologies, Atlanta, GA. Thin layer chromatography was performed using Analtech silica gel plates. The TLC plates were visualized using iodine vapor and/or UV light. A Hewlett-Packard diode array UV/VIS spectrophotometer was used in the enzyme assays and inhibition studies.

Representative Syntheses

Synthesis of compound 2—To a solution of 4-n-propyl-5-methyl- 2-chloromethyl-1, 2, 5- thiadiazolin-3-one 1, 1 dioxide **1** (3.38 g; 14.04 mmol) and thiolacetic acid (2.14 g; 28.08 mmol) in dry acetonitrile (30 mL) kept in an ice bath was added dropwise a solution of triethylamine (1.70 g; 16.8 mmol) in acetonitrile (5 mL). The mixture was allowed to warm to room temperature and stirred for 2 days. The solvent was removed on the rotovac and the residue was taken up in ethyl acetate (100 mL) and washed with 5% aqueous HCl (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate. Removal of the

solvent left a crude product which was purified by flash chromatography using hexane/ethyl acetate to yield 3.50 g (89% yield) of an oily product. ^1H NMR (CDCl_3): δ 0.95-1.00 (t, 3H), 1.38 (m, 1H), 1.45 (m, 1H), 1.80 (m, 1H), 1.90 (m, 1H), 2.40 (s, 3H), 2.90 (s, 3H), 3.82 (t, 1H), 5.10 (q, 2H).

Synthesis of compound 4—Thioester **2** (2.40 g; 8.56 mmol) was dissolved in CDCl_3 (7 mL) and cooled to 5 °C using an ice bath and kept under nitrogen. Sulfury chloride (1.6 mL; 17.12 mmol) was then added and the mixture was stirred for 3 h. NMR analysis showed that most of the starting material had reacted. The solvent and sulfuryl chloride were then removed at 5 °C using a vacuum pump (40 minutes). The residue was redissolved in dry methylene chloride (10 mL) and then cooled to -78 °C using a dry ice/acetone bath. A mixture of (L) Phe-OCH₃ hydrochloride (2.77 g; 12.84 mmol) and N-methyl morpholine (1.30 g; 12.84 mmol) in methylene chloride (15 mL) was added to the solution and the resulting mixture was stirred at -78 °C for 1 h and then allowed to warm up to 25 °C by stirring overnight. The precipitate was filtered off and the filtrate was concentrated, leaving a crude product (3.28 g) which was purified by flash chromatography using hexane/ether. A pure product **3** was obtained (1.04 g; 29% yield) as a colorless oil (^1H NMR: δ 1.98 (m, 3H), 1.38 (m, 1H), 1.50 (m, 1H), 1.80 (m, 1H), 1.98 (m, 1H), 2.90 (s, 3H), 3.00 (m, 2H), 3.70 (s, 3H), 3.80 (t, 1H), 3.90 (m, 1H), 4.50-4.78 (dd, 2H), 7.20-7.30 (m, 5H), however, sulfinamide **3**, as well as the rest of the synthesized sulfinamides were found to color on standing, consequently they were used in the next step without purification.

A solution of sulfinamide **3** (1.98 g; 4.76 mmol) in dry methylene chloride (10 mL) was cooled in an ice bath and then treated with 77% m-chloroperbenzoic acid (4.27 g; 19.06 mmol). The mixture was stirred overnight and the solvent removed on the rotovac. The residue was taken up in ethyl acetate (50 mL) and washed with saturated sodium bicarbonate (3 × 10 mL), brine (3 × 10 mL) and the organic extract was dried over anhydrous sodium sulfate. Removal of the solvent left a crude product which was purified using flash chromatography (hexane/ethyl acetate eluents), yielding compound **4** as pure white solid (0.83 g; 39% yield), mp 129-132 °C. ^1H NMR (CDCl_3): δ 0.98 (t, 3H), 1.40 (m, 2H), 1.5 (d, 3H), 1.85 (m, 1H), 1.95 (m, 1H), 2.95 (s, 3H), 3.80 (s, 3H), 4.00 (t, 1H), 4.30 (m, 1H), 4.85 (d, 1H), 5.10 (d, 1H), 5.40 (d, 1H).

Compound 5—mp 87-90 °C. ^1H NMR (CDCl_3): δ 0.95 (m, 6H), 1.45 (m, 4H), 1.80 (m, 3H), 1.95 (m, 1H), 2.92 (s, 3H), 3.80 (s, 3H), 3.96 (t, 1H), 4.20 (q, 1H), 4.95-5.10 (dd, 2H), 5.40 (d, 1H).

Compound 6—mp 119-121 °C. ^1H NMR (CDCl_3): δ 0.95 (t, 3H), 1.35 (m, 1H), 1.45 (m, 1H), 1.82 (m, 1H), 1.90 (m, 1H), 2.90 (s, 3H), 3.17 (t, 2H), 3.75 (s, 3H), 3.93 (t, 1H), 4.50 (t, 1H), 4.65-4.85 (dd, 2H), 7.22 (m, 5H).

Compound 7—mp 99-101 °C. ^1H NMR (CDCl_3): δ 0.95 (t, 3H), 1.35 (m, 1H), 1.45 (m, 1H), 1.82 (m, 1H), 1.90 (m, 1H), 2.90 (s, 3H), 3.17 (t, 2H), 3.75 (s, 3H), 3.93 (t, 1H), 4.50 (t, 1H), 4.65-4.85 (dd, 2H), 7.20 (m, 5H).

Compound 8—mp 74-76 °C. ^1H NMR (CDCl_3): δ 0.95 (t, 3H), 1.41 (m, 1H), 1.50 (m, 1H), 1.85 (m, 1H), 1.95 (m, 1H), 2.98 (s, 3H), 3.75 (s, 3H), 3.90 (m, 2H), 3.95 (t, 1H), 4.40 (m, 1H), 4.55 (dd, 2H), 5.05 (dd, 2H), 5.70 (d, 1H), 7.32 (m, 5H).

Compound 9—mp 80-82 °C. ^1H NMR (CDCl_3): δ 0.95 (t, 3H), 1.40 (m, 1H), 1.50 (m, 1H), 1.85 (m, 1H), 1.95 (m, 1H), 2.75 (br s, 1H), 2.95 (s, 3H), 3.80 (s, 3H), 3.98 (d, 2H), 4.02 (t, 1H), 4.32 (s, 1H), 5.00 (dd, 2H), 5.90 (br s, 1H).

Compound 10—oil. ^1H NMR (CDCl_3): δ 0.95 (t, 3H), 1.45 (m, 6H), 1.80 (m, 4H), 2.95 (s, 3H), 3.20 (m, 2H), 3.80 (s, 3H), 4.00 (t, 1H), 4.20 (m, 1H), 4.80-5.10 (dd, 2H), 5.00 (m, 2H), 5.50 (d, 1H), 7.40 (m, 5H).

Compound 11—oil. ^1H NMR (CDCl_3): δ 0.95 (t, 3H), 1.48 (m, 6H), 1.85 (m, 4H), 2.90 (s, 3H), 3.20 (q, 2H), 3.75 (s, 3H), 3.95 (t, 1H), 4.19 (q, 1H), 4.95 (q, 2H), 5.10 (s, 2H), 5.49 (d, 1H), 7.32 (m, 5H).

Enzyme Assays and Inhibition Studies

Human neutrophil elastase—HNE was assayed by mixing 10 μL of a 70 μM enzyme solution in 0.05 M sodium acetate/0.5 M NaCl buffer, pH 5.5, 10 μL dimethyl sulfoxide and 980 μL of 0.1 M HEPES buffer containing 0.5 M NaCl, pH 7.25, in a thermostated cuvette. A 100 μL aliquot was transferred to a thermostated cuvette containing 880 μL 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25, and 20 μL of a 70 μM solution of MeOSuc-Ala-Ala-Pro-Val p-nitroanilide, and the change in absorbance was monitored at 410 nm for 60 seconds. In a typical inhibition run, 10 μL of inhibitor (700 μM) in dimethyl sulfoxide was mixed with 10 μL of 70 μM enzyme solution and 980 μL 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25, and placed in a constant temperature bath. Aliquots (100 μL) were withdrawn at different time intervals and transferred to a cuvette containing 20 μL of MeOSuc-Ala-Ala-Pro-Val p-nitroanilide (7 mM) and 880 μL 0.1 M HEPES/0.5 M NaCl buffer. The absorbance was monitored at 410 nm for 60 seconds.

Progress curves were generated by adding 5 μL of a 2.0 μM HNE solution in 0.05 M sodium acetate buffer, pH 5.5, to 10 μL of inhibitor (50 μM solution in DMSO), 15 μL of substrate (MeOSuc-Ala-Ala-Pro-Val pNA, 7 mM in DMSO) and 970 μL 0.1 M HEPES buffer/0.5 M NaCl buffer, pH 7.25, and the absorbance was monitored at 410 nm for ten minutes.

Human neutrophil proteinase 3—Twenty microliters of a 32.0 mM 5, 5'-Dithio-bis(2-nitrobenzoic acid) in DMSO and 10 μL of a 3.45 μM solution of human proteinase 3 in 0.1 M phosphate/0.25 M NaCl buffer, pH 6.50 (final enzyme concentration: 34.5 nM) were added to a cuvette containing a solution of 940 μL 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25, 10 μL of a 0.86 mM inhibitor solution in DMSO (final inhibitor concentration: 8.6 μM) and 20 μL of a 12.98 mM solution of Boc-Ala-Ala-NVa-SBzl in DMSO, and the change in absorbance was monitored at 410 nm for 2 minutes. A control (hydrolysis) was also run under the same conditions by adding 20 μL of a 32.0 mM 5, 5'-Dithio-bis(2-nitrobenzoic acid) solution in DMSO and 10 μL of a 3.45 μM solution of human proteinase 3 in 0.1 M phosphate buffer, pH 6.50 (final enzyme concentration: 34.5 nM) to a cuvette containing a solution of 940 μL 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25, 10 μL DMSO, and 20 μL of a 12.98 mM solution of Boc-Ala-Ala-NVa-SBzl in DMSO, and the change in absorbance was monitored at 410 nm for 2 minutes.

Human neutrophil cathepsin G—Ten microliters of a 6.8 μM solution of human neutrophil cathepsin G in 0.05 M sodium acetate/0.05 M NaCl buffer, pH 5.38, was added to a solution containing 10 μL of inhibitor (1.7 mM solution in DMSO), and 970 μL of 0.1 M HEPES buffer, pH 7.50. The mixture was incubated for 30 minutes, 10 μL of substrate (N-Succinyl Ala-Ala-Pro-Phe p-nitroanilide, 85 mM in DMSO) was added and the absorbance was monitored at 410 nm for 10 minutes.

Bovine trypsin

Incubation method: Bovine trypsin was assayed by mixing 10 μL of a 500 μM enzyme solution in 0.1 M TRIS-HCl/0.01 M CaCl_2 buffer, pH 7.2, 10 μL DMSO and 980 μL of 0.025 M phosphate/0.1 M NaCl buffer, pH 7.51, in a thermostated test tube. A 100 μL aliquot was

transferred to a thermostated cuvette containing 890 μL 0.025 M phosphate/0.1 M NaCl buffer, pH 7.51, and 10 μL of a 60 mM solution of N-p-Tosyl-Gly-Pro-Lys p-nitroanilide in DMSO and the change in absorbance was monitored at 410 nm for sixty seconds. In a typical inhibition run, 10 μL of inhibitor (12.5 mM) in DMSO was mixed with 10 μL of a 500 μM enzyme solution in 0.1 M TRIS-HCl/0.01 M CaCl_2 buffer, pH 7.2, and 980 μL of 0.1 M TRIS-HCl/0.01 M CaCl_2 buffer, pH 7.51, and placed in a constant temperature bath. Aliquots (100 μL) were withdrawn at different time intervals and transferred to a cuvette containing 10 μL of a 60 mM solution of N-p-Tosyl-Gly-Pro-Lys p-nitroanilide in DMSO and 890 μL of 0.025 M phosphate/0.1 M NaCl buffer, pH 7.51. The absorbance was monitored at 410 nm for sixty seconds. The pseudo first-order rate constants were obtained from plots of $\ln(v/v_0)$ vs time and are the average of two determinations.

Acknowledgements

Financial support of this work by the National Institutes of Health (HL 57788) is gratefully acknowledged.

References

- (a) Churg A, Wright JL. *Curr Opin Pulm Med* 2005;11:153–159. [PubMed: 15699789] (b) Barnes PJ. *Pharmacol Rev* 2004;56:515–548. [PubMed: 15602009] (c) Barnes PJ, Stockley RA. *Eur Respir J* 2005;25:1984–1106. (d) Shapiro SD, Ingenito EP. *Am J Respir Cell Mol Biol* 2005;32:367–372. [PubMed: 15837726] (e) Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. *Am J Pathol* 2003;163:2329–2335. [PubMed: 14633606] (f) Moraes TJ, Chow CW, Downey GP. *Crit Care Med* 2003;31:S189–S194. [PubMed: 12682439] (h) Balfour-Lynn IM. *J Royal Soc Med* 1999;92:S23–S30. (i) Van Der Geld YM, Limburg PC, Kallenberg CG. *J Leuk Biol* 2001;69:177–190.
- (a) MacNee W. *Proc Am Thorac Soc* 2005;2:50–60. [PubMed: 16113469] (b) Bowler RP, Barnes PJ, Crapo JD. *J Chronic Obstructive Pulmonary Disease* 2004;1:255–277.
- (a) Aoshiba K, Yokohori N, Nagai A. *Am J Respir Cell Mol Biol* 2003;28:555–562. [PubMed: 12707011] (b) Tudor RM, Petrache I, Elias JA, Voelkel NF, Henson PM. *Am J Respir Cell Mol Biol* 2003;28:551–554. [PubMed: 12707010]
- (a) Shapiro SD, Ingenito EP. *Am J Respir Cell Mol Biol* 2005;32:367–372. [PubMed: 15837726] (b) Stockley RA. *Am J Respir Crit Care Med* 1999;160:S49–S52. [PubMed: 10556170]
- (a) Rennard SI. *Am J Respir Crit Care Med* 2005;160:S12–S16. [PubMed: 10556162] (b) Pham CTN. *Nat Rev Immunol* 2006;6:541–550. [PubMed: 16799473] (c) Snider GL. *Am J Respir Crit Care Med* 2003;167:1045–1049. [PubMed: 12684241]
- Wiedow G, Meyer-Hoppert U. *J Int Med* 2005;257:319–328.
- (a) Abbenante G, Fairlie DP. *Med Chem* 2005;1:71–104. [PubMed: 16789888] (b) Ohbayashi H. *Expert Opin Investig Drugs* 2002;11:965–980.
- (a) Wei L, Lai Z, Gan X, Alliston KR, Zhong J, Epp JB, Tu J, Perera AB, Van Stipdonk M, Groutas WC. *Arch Biochem Biophys* 2004;429:60–70. [PubMed: 15288810] (b) Lai Z, Gan X, Wei L, Alliston KR, Yu H, Li YH, Groutas WC. *Arch Biochem Biophys* 2004;429:191–197. [PubMed: 15313222]
- Nomenclature used is that of Schechter I, Berger A. *Biochem Biophys Res Comm* 1967;27:157–162. [PubMed: 6035483], where $S_1, S_2, S_3, \dots, S_n$ and $S'_1, S'_2, S'_3, \dots, S'_n$ correspond to the enzyme subsites on either side of the scissile bond. Each subsite accommodates a corresponding amino acid residue side chain designated $P_1, P_2, P_3, \dots, P_n$ and $P'_1, P'_2, P'_3, \dots, P'_n$ of the substrate or (inhibitor). S_1 is the primary substrate specificity subsite, and $P_1-P'_1$ is the scissile bond.
- Morrison JF, Walsh CT. *Adv Enzymol* 1988;61:201–301. [PubMed: 3281418]
- Wouters EF. *Proc Am Thorac Soc* 2005;2:26–33. [PubMed: 16113466]
- Dinwiddie R. *Respiration* 2000;67:3–8. [PubMed: 10705255]
- Rao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. *J Clin Invest* 1988;82:1963–1973. [PubMed: 3198760]
- Groutas WC, Kunag R, Venkataraman R, Epp JB, Ruan S, Prakash O. *Biochemistry* 1997;36:4739–4750. [PubMed: 9125494]

15. (a) Imperiali B, Abeles RH. *Biochemistry* 1987;26:4474–4477. [PubMed: 3663602] (b) Groutas WC, Epp JB, Kuang R, Ruan S, Chong LS, Venkataraman R, Tu J, He S, Yu H, Fu Q, Li YH, Truong TM, Vu NT. *Arch Biochem Biophys* 2001;385:162–169. [PubMed: 11361013] (c) Groutas WC, He S, Kuang R, Ruan S, Tu J, Chan HK. *Bioorg Med Chem* 2001;9:1543–1548. [PubMed: 11408173]
16. Dai Y, Hedstrom L, Abeles RH. *Biochemistry* 2000;39:6498–6502. [PubMed: 10828965]
17. (a) Kuang R, Epp JB, Ruan S, Yu H, Huang P, He S, Tu J, Schechter NM, Turbov J, Froelich CJ, Groutas WC. *J Am Chem Soc* 1999;121:8128–8129. (b) Groutas WC, Kuang R, Ruan S, Epp JB, Venkataraman R, Truong TM. *Bioorg Med Chem* 1998;6:661–671. [PubMed: 9681132] (c) Kuang R, Venkataraman R, Ruan S, Groutas WC. *Bioorg Med Chem Lett* 1998;8:539–544. [PubMed: 9871614] (d) Kuang R, Epp JB, Ruan S, Chong LS, Venkataraman R, Tu J, He S, Truong TM, Groutas WC. *Bioorg Med Chem* 2000;8:1005–1016. [PubMed: 10882012] (e) He S, Kuang R, Venkataraman R, Tu J, Truong TM, Chan HK, Groutas WC. *Bioorg Med Chem* 2000;8:1713–1717. [PubMed: 10976518]
18. (a) Bode W, Meyer EF, Powers JC. *Biochemistry* 1989;28:1951–1963. [PubMed: 2655701] (b) Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MNG. *J Mol Biol* 1996;261:267–278. [PubMed: 8757293]
19. (a) Koehl C, Knight CG, Bieth JG. *J Biol Chem* 2003;278:12609–12612. [PubMed: 12538645] (b) Korkmaz B, Attucci S, Hazouard E, Ferrandiere M, Jourdan ML, Brillard-Bourdet M, Juliano L, Gauthier F. *J Biol Chem* 2002;277:39074–39081. [PubMed: 12114510] (c) Korkmaz B, Attucci S, Moreau T, Godat E, Juliano L, Gauthier F. *Am J Respir Cell Mol Biol* 2004;30:801–807. [PubMed: 14693667] (d) Hajjar E, Korkmaz B, Gauthier F, Brandsdal BO, Witko-Sarsat V, Reuter N. *J Med Chem* 2006;49:1248–1260. [PubMed: 16480262]
20. Korkmaz B, Hajjar E, Kalupov T, Reuter N, Brillard-Bourdet M, Moreau T, Juliano L, Gauthier F. *J Biol Chem* 2007;282:1989–1997. [PubMed: 17088257]
21. Hof P, Mayr I, Huber R, Korzus E, Potempa J, Travis J, Powers JC, Bode W. *EMBO J* 1995;15:5481. [PubMed: 8896442]

Figure 2.

Progress curves for the inhibition of human neutrophil elastase (HNE) by inhibitor **4**.

Absorbance was monitored at 410 nm for reaction solutions containing 10 nM HNE, 105 μ M MeOSuc-AAPV p-nitroanilide, and the inhibitor at the indicated inhibitor to enzyme ratios in 0.1 M HEPES buffer containing 0.5 M NaCl, pH 7.25, and 2.5% DMSO. The temperature was maintained at 25°C, and reactions were initiated by the addition of enzyme.

Figure 3.

Time dependent loss of enzymatic activity. Percent remaining activity versus time plot obtained by incubating inhibitor **4** (7 μ M) with human neutrophil elastase (700 nM) in 0.1 M HEPES buffer containing 0.5 M NaCl, pH 7.25, and 1% DMSO. Aliquots were withdrawn at different time intervals and assayed for enzymatic activity using MeOSuc-AAPV p-NA by monitoring the absorbance at 410 nm.

Figure 4.

Time dependent loss of enzymatic activity. Percent remaining activity versus time plot obtained by incubating inhibitor **4** (0.125 mM) with bovine trypsin (5 μ M) in 0.025 M phosphate buffer containing 0.1 M NaCl, pH 7.51, and 1% DMSO. Aliquots were withdrawn at different time intervals and assayed for enzymatic activity using N-(p-Tosyl)-Gly-Pro-Lys p-NA by monitoring the absorbance at 410 nm.

Scheme 1.
Synthesis of inhibitors 4–11

Table 1

Inhibitory activity of compounds **4-11** toward human neutrophil elastase, proteinase 3, cathepsin G, and bovine trypsin.

(I)						
Compound ^a	R ₃	HNE	PR 3	k _{inact} /K _I M ⁻¹ s ⁻¹	Cat G	Trypsin ^b
4	(L) CH ₃	1,050	inactive ^c		inactive ^c	ND ^d
5	(L) CH ₃ (CH ₂) ₂	34,650	inactive		inactive	19
6	(L) PhCH ₂	41,750	inactive		inactive	50
7	(D) PhCH ₂	9,760	inactive		inactive	ND
8	(L) PhCH ₂ OCH ₂	16,870	inactive		inactive	60
9	(L) CH ₂ OH	1,100	inactive		inactive	12
10	(L) (CH ₂) ₄ NH ₂	12,900	inactive		inactive	ND
11	(L) (CH ₂) ₄ NHCbz	6,900	inactive		inactive	ND

^aP₁=n-propyl, R₂=methyl

^bk_{obs}/[I] M⁻¹ s⁻¹ values determined using the incubation method (see text for details)

^c[I]/[E] = 250 for 30 minutes

^dNot Determined